This is where the end of January readout is coming from:
"2024 Deliverables > 1st dose co-hort complete" + it is now December + trial design with Primary Outcome 28 days after treatment, and
"CHM CDH17 Clinical Development Strategy" pink circle top left on the time line shortly after "2024".
These graphs were used between July and December.
Regarding your question regarding 3/3 and 5/5 - homest answer, I don't know and I couldn't find anything to confirm my suspicion that it is cohort related based on dose escalation:
Just a guess since neither clinicaltrials.gov (only mentions a 3+3 study design) nor the company presentations showed the number of patients per cohort as far as I'm aware, but happy to be proven wrong.
CHM Price at posting:
0.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)